The Role of TLRs in Anti-cancer Immunity and Tumor Rejection

Zuzanna Urban-Wojciuk; Mohd M. Khan; Mohd M. Khan; Benjamin L. Oyler; Robin Fåhraeus; Robin Fåhraeus; Robin Fåhraeus; Robin Fåhraeus; Natalia Marek-Trzonkowska; Natalia Marek-Trzonkowska; Aleksandra Nita-Lazar; Ted R. Hupp; Ted R. Hupp; Ted R. Hupp; David R. Goodlett; David R. Goodlett

doi:10.3389/fimmu.2019.02388

Frontiers in Immunology (Oct 2019)

The Role of TLRs in Anti-cancer Immunity and Tumor Rejection

Zuzanna Urban-Wojciuk,
Mohd M. Khan,
Mohd M. Khan,
Benjamin L. Oyler,
Robin Fåhraeus,
Robin Fåhraeus,
Robin Fåhraeus,
Robin Fåhraeus,
Natalia Marek-Trzonkowska,
Natalia Marek-Trzonkowska,
Aleksandra Nita-Lazar,
Ted R. Hupp,
Ted R. Hupp,
Ted R. Hupp,
David R. Goodlett,
David R. Goodlett

Affiliations

Zuzanna Urban-Wojciuk: International Centre for Cancer Vaccine Science (ICCVS), University of Gdaǹsk, Gdaǹsk, Poland
Mohd M. Khan: Laboratory of Immune System Biology (LISB), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, United States
Mohd M. Khan: University of Maryland School of Medicine, Baltimore, MD, United States
Benjamin L. Oyler: University of Maryland School of Medicine, Baltimore, MD, United States
Robin Fåhraeus: International Centre for Cancer Vaccine Science (ICCVS), University of Gdaǹsk, Gdaǹsk, Poland
Robin Fåhraeus: Department of Medical Biosciences, Umeå University, Umeå, Sweden
Robin Fåhraeus: Université Paris 7, INSERM, UMR 1162, Paris, France
Robin Fåhraeus: Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czechia
Natalia Marek-Trzonkowska: International Centre for Cancer Vaccine Science (ICCVS), University of Gdaǹsk, Gdaǹsk, Poland
Natalia Marek-Trzonkowska: Laboratory of Immunoregulation and Cellular Therapies, Department of Family Medicine, Medical University of Gdaǹsk, Gdaǹsk, Poland
Aleksandra Nita-Lazar: Laboratory of Immune System Biology (LISB), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, United States
Ted R. Hupp: International Centre for Cancer Vaccine Science (ICCVS), University of Gdaǹsk, Gdaǹsk, Poland
Ted R. Hupp: Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czechia
Ted R. Hupp: Cell Signaling Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom
David R. Goodlett: International Centre for Cancer Vaccine Science (ICCVS), University of Gdaǹsk, Gdaǹsk, Poland
David R. Goodlett: Department of Microbial Pathogenesis, University of Maryland School of Dentistry, Baltimore, MD, United States

DOI: https://doi.org/10.3389/fimmu.2019.02388
Journal volume & issue: Vol. 10

Abstract

Read online

In recent years, a lot of scientific interest has focused on cancer immunotherapy. Although chronic inflammation has been described as one of the hallmarks of cancer, acute inflammation can actually trigger the immune system to fight diseases, including cancer. Toll-like receptor (TLR) ligands have long been used as adjuvants for traditional vaccines and it seems they may also play a role enhancing efficiency of tumor immunotherapy. The aim of this perspective is to discuss the effects of TLR stimulation in cancer, expression of various TLRs in different types of tumors, and finally the role of TLRs in anti-cancer immunity and tumor rejection.

Published in Frontiers in Immunology

ISSN: 1664-3224 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Website: http://journal.frontiersin.org/journal/immunology

About the journal

Abstract

Keywords